A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs AMG 890 (Primary)
- Indications Cardiovascular disorders
- Focus Adverse reactions; First in man
- Sponsors Amgen
- 29 Oct 2019 Planned End Date changed from 30 Jun 2020 to 3 Mar 2020.
- 05 Aug 2019 According to an Arrowhead Pharmaceuticals media release, Amgen expects to share initial data from the study late this year or early next year.
- 23 Jul 2019 Planned primary completion date changed from 11 Mar 2020 to 3 Mar 2020.